A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...

Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related ...

Pasithea Therapeutics announced promising preclinical data for PAS-004, a next-generation MEK inhibitor, which shows superior effectiveness in inhibiting the ETS2 pathway associated with ...

MEK inhibitors are frequently associated with cutaneous adverse events in pediatric patients, and binimetinib was associated with more severe reactions than selumetinib in a retrospective study, which ...

BRAF and MEK inhibitors are effective in treating resectable melanoma with BRAF V600 mutations, achieving significant pathological responses. The combination therapy significantly improves ...

Nearly a fifth of patients with cancer being treated with mitogen-activated protein kinase (MEK) inhibitors in clinical trials developed an ocular adverse event, according to a research letter ...

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed. Overall, 53 ...

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma The following represents disclosure information ...

Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events ...